Skip to main content

Intracerebral Hemorrhage

13
Pipeline Programs
26
Companies
19
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
6
0
6
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

23 companies ranked by most advanced pipeline stage

Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
3 programs
2
1
StatinsPhase 3
DeferoxaminePhase 21 trial
Deferoxamine MesylatePhase 21 trial
Active Trials
NCT01662895Terminated42Est. May 2018
NCT02175225Completed294Est. May 2018
Arrowhead Pharmaceuticals
1 program
1
StatinsPhase 3
Utah Medical
Utah MedicalIreland - Dublin
1 program
1
StatinsPhase 3
Grand Medical
Grand MedicalIsrael - Ramat Gan
1 program
1
StatinsPhase 31 trial
Active Trials
NCT03936361Recruiting1,456Est. Dec 2029
Eden Medical
Eden MedicalMN - South Haven
1 program
1
StatinsPhase 3
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
1
StatinsPhase 3
Baxter
BaxterCosta Rica - Cartago
1 program
1
AlbuminPhase 2
Biocorp
BiocorpFrance - Issoire
1 program
1
CN-105Phase 21 trial
Active Trials
NCT06255977Unknown240Est. Aug 2024
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
Glycerly TrinitratePhase 21 trial
Active Trials
NCT01811693Terminated4Est. Dec 2013
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
NXY-059Phase 21 trial
Active Trials
NCT00075959Completed600Est. Jan 2006
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-05230907Phase 11 trial
Active Trials
NCT02687191Terminated21Est. Jan 2018
Nico
NicoIN - Indianapolis
2 programs
Early Surgical Hematoma EvacuationN/A1 trial
Viz RECRUITN/A1 trial
Active Trials
NCT02880878Completed300Est. Feb 2023
NCT03865979Completed10Est. Apr 2023
Viz.ai
Viz.aiCA - San Francisco
2 programs
Viz ICH VOLUMEN/A1 trial
Viz RECRUITN/A
Active Trials
NCT04733638Completed1,000Est. Apr 2023
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
2 programs
Recombinant Activated Factor VIIPHASE_31 trial
Recombinant Factor VIIaPHASE_31 trial
Active Trials
NCT03496883Active Not Recruiting860Est. Jan 2028
NCT07227246Recruiting350Est. Jun 2029
Penumbra
PenumbraALAMEDA, CA
1 program
Artemis Neuro Evacuation DeviceN/A1 trial
Active Trials
NCT04178746Terminated4Est. Jun 2021
Chiesi
ChiesiBrazil - Santana de Parnaíba
1 program
Clevidipine InjectionN/A1 trial
Active Trials
NCT06402968Recruiting1,000Est. Jul 2028
Chiesi USA
Chiesi USANC - Cary
1 program
Clevidipine InjectionN/A
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
EuthyroxN/A1 trial
Active Trials
NCT06353555Recruiting100Est. Dec 2025
Baxter International
1 program
AlbuminPHASE_21 trial
Active Trials
NCT00990509Terminated14Est. Jun 2013
Bioxodes
BioxodesBelgium - Gosselies
1 program
Ir-CPIPHASE_21 trial
Active Trials
NCT05970224Active Not Recruiting23Est. Jul 2027
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Intravenous nicardipine hydrochloridePHASE_31 trial
Active Trials
NCT01176565Terminated1,000Est. Mar 2016
Hamilton medical
Hamilton medicalSwitzerland - Bonaduz
1 program
StatinsPHASE_3
Genentech
GenentechCA - Oceanside
1 program
rt-PAPHASE_31 trial
Active Trials
NCT01827046Completed499Est. Sep 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Novo NordiskRecombinant Factor VIIa
Novo NordiskRecombinant Activated Factor VII
Grand MedicalStatins
Genentechrt-PA
Heidelberg PharmaIntravenous nicardipine hydrochloride
BioxodesIr-CPI
BiocorpCN-105
Oregon TherapeuticsDeferoxamine Mesylate
Angeles TherapeuticsGlycerly Trinitrate
Oregon TherapeuticsDeferoxamine
Baxter InternationalAlbumin
AstraZenecaNXY-059
PfizerPF-05230907
ChiesiClevidipine Injection
UNION therapeuticsEuthyrox

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 7,817 patients across 19 trials

NCT07227246Novo NordiskRecombinant Factor VIIa

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

Start: May 2025Est. completion: Jun 2029350 patients
Phase 3Recruiting
NCT03496883Novo NordiskRecombinant Activated Factor VII

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

Start: Dec 2021Est. completion: Jan 2028860 patients
Phase 3Active Not Recruiting
NCT03936361Grand MedicalStatins

Statins In Intracerbral Hemorrhage

Start: Jun 2020Est. completion: Dec 20291,456 patients
Phase 3Recruiting
NCT01827046Genentechrt-PA

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III

Start: Dec 2013Est. completion: Sep 2018499 patients
Phase 3Completed
NCT01176565Heidelberg PharmaIntravenous nicardipine hydrochloride

Antihypertensive Treatment of Acute Cerebral Hemorrhage-II

Start: May 2011Est. completion: Mar 20161,000 patients
Phase 3Terminated
NCT05970224BioxodesIr-CPI

A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage

Start: Nov 2023Est. completion: Jul 202723 patients
Phase 2Active Not Recruiting
NCT06255977BiocorpCN-105

A Study Evaluating the Safety and Efficacy of Neuroprotective Peptide CN-105 Peptide in Patients With Acute Supratentorial Intracerebral Hemorrhage

Start: Aug 2022Est. completion: Aug 2024240 patients
Phase 2Unknown
NCT02175225Oregon TherapeuticsDeferoxamine Mesylate

Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

Start: Oct 2014Est. completion: May 2018294 patients
Phase 2Completed
NCT01811693Angeles TherapeuticsGlycerly Trinitrate

Field Administration of Stroke Therapy-Blood Pressure Lowering

Start: Apr 2013Est. completion: Dec 20134 patients
Phase 2Terminated
NCT01662895Oregon TherapeuticsDeferoxamine

High-Dose Deferoxamine in Intracerebral Hemorrhage

Start: Mar 2013Est. completion: May 201842 patients
Phase 2Terminated
NCT00990509Baxter InternationalAlbumin

Albumin for Intracerebral Hemorrhage Intervention

Start: Sep 2009Est. completion: Jun 201314 patients
Phase 2Terminated
NCT00075959AstraZenecaNXY-059

Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

Start: Aug 2004Est. completion: Jan 2006600 patients
Phase 2Completed
NCT02687191PfizerPF-05230907

Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage

Start: Nov 2016Est. completion: Jan 201821 patients
Phase 1Terminated
NCT06402968ChiesiClevidipine Injection

Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage

Start: Jun 2024Est. completion: Jul 20281,000 patients
N/ARecruiting
NCT06353555UNION therapeuticsEuthyrox

Efficacy of Thyroid Hormone Replacement for Secondary Hypothyroidism Following Intracerebral Hemorrhage

Start: Oct 2023Est. completion: Dec 2025100 patients
N/ARecruiting
NCT04733638Viz.aiViz ICH VOLUME

ADVANCE- Automated Detection and Volumetric Assessment of ICH

Start: Jan 2021Est. completion: Apr 20231,000 patients
N/ACompleted
NCT03865979NicoViz RECRUIT

AI ENRICH - AI Detection of ICH

Start: Jan 2020Est. completion: Apr 202310 patients
N/ACompleted
NCT04178746PenumbraArtemis Neuro Evacuation Device

PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase

Start: Sep 2019Est. completion: Jun 20214 patients
N/ATerminated
NCT02880878NicoEarly Surgical Hematoma Evacuation

ENRICH: Early MiNimally-invasive Removal of IntraCerebral Hemorrhage (ICH)

Start: Dec 2016Est. completion: Feb 2023300 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs, potential near-term approvals
4 actively recruiting trials targeting 7,817 patients
26 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.